Prelude Therapeutics appoints Katina Dorton to board; Mardi Dier resigns

Prelude Therapeutics Inc

Mardi Dier resigned as Class III director effective Oct 17, 2025, not due to any disagreement.
Katina Dorton, J.D., MBA, appointed as Class III director and Audit Committee Chair, effective Oct 17.
Dorton brings 30+ years of healthcare finance and board experience; served as CFO at NodThera.
Dorton received option to purchase 76,000 shares vesting over 3 years under 2020 Equity Incentive Plan.
Dorton also serves on boards of Fulcrum Therapeutics (FULC) and TScan Therapeutics (TCRX).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.